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adjusted 70 and CPI-H adjusted 40) and for basic refund
category 147 (61; 35), respectively. In 1990 = 100 index
the respective ﬁgures were: all drugs 110 (88; 68), pre-
scription based 105 (83; 64), reimbursed 102 (81; 62),
Basic Refund (“50%”) 102 (81; 62), Lower Special
Refund (“75%”) 102 (81; 62) and Higher Special Refund
(“100%”) 103 (82; 63). CONCLUSIONS: Nominal drug
wholesale prices have increased in Finland since 1980 and
also slightly from 1990, but real prices have constantly
decreased. Depending from the adjustment index used,
the real prices of all drugs have decreased from 30–60%
since 1980, or 12–33% since 1990. For reimbursed drugs
the development was similar. The prices in general, and
in the Basic Refund category have decreased 19–38%
since 1990, and even 40–75% since 1980. Since the effec-
tiveness of drugs has not decreased during the time period
studied, we suggest that the drug treatment has clearly
become more cost-effective in Finland.
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OBJECTIVES: To compare the periods of market 
exclusivity for branded pharmaceuticals in Canada with
the United States, the United Kingdom, and France.
METHODS: We identiﬁed the 50 top selling generic mol-
ecules in Canada. The dates of ﬁrst sale of the original
brand and corresponding ﬁrst generic for each molecule
were compared to determine the period of market exclu-
sivity of each branded product. Corresponding data were
collected and periods of exclusivity calculated for the US,
UK and France. In cases where a generic had yet to be
introduced in a comparator country, the period of market
exclusivity was calculated as of May 2003. Average
market exclusivity for the products in the study was cal-
culated for each country. RESULTS: The average period
of market exclusivity for the 50 brands in Canada was
10.7 years, considerably lower than in the other countries
(US 12.1; UK 15.0; France 19.1 years). There was incom-
plete international information for nine of the ﬁfty mol-
ecules. When the analysis was restricted to the remaining
41 products the results were similar (Canada 9.8; US
12.0; UK 15.0; France 17.0 years). Although the sample
products represent the 50 top selling generic molecules in
Canada, many were not yet marketed as generics in the
comparator countries (US 6; UK 11; France 21). CON-
CLUSIONS: The analysis indicates that on average,
market exclusivity for the same brands in Canada was
signiﬁcantly shorter than in the US, UK and France. A
more favourable regulatory climate for generic drugs in
Canada (early working, faster generic approval times,
mandatory generic substitution laws etc.) and longer
approval times for brand drugs may account for some 
of the differences. Despite changes in patent legislation
(1987, 1993) to restore patent protection, the analysis
does not suggest a trend toward longer periods of market
exclusivity for newer brands in Canada.
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OBJECTIVES: When the selection of treatments ﬁnanced
by public money is considered, rational decisions to incor-
porate a new drug in clinical practice has to be even more
exact. Here, we analyse the incorporation of new medi-
cines ﬁnanced by the Spanish National Health Service
(NHS) into the clinical practice from 1996 to 2000. The
Spanish NHS covers more than 95% of the population.
METHODS: A retrospective study has been made, select-
ing new medicines classiﬁed following the degree of ther-
apeutic innovation at the moment of authorisation (A*,
A, B, C, and D), according to the criterion of the Min-
istry of Health and Consume (MHC). Consume data were
provided by the MHC database. They were expressed as
Price for Sale Direct to Customer, tax-free (PVP) by means
of Millions of Pesetas (MPTA) and in number of con-
sumed units. The rapid incorporation of new medicines
into the clinical practice (the one-hundred tops) and the
evolution of their consume were the indicators used.
RESULTS: The total number of new drugs selected was
68 (19, 20, 19, 8, and 2 in the years 96, 97, 98, 99, and
00, respectively). None of them were categorised in type
A*. Mostly were types B (29.4%) and C (67.6%). From
those, Olanzapine (96), Atorvastatin (97), Cerivastatine
(98), Clopidogrel (99), or Celecoxib (00), among others,
had a very fast incorporation. Analysing the evolution of
new drug consumption, it detected that some of them
have been withdrawn from the clinical practice because
of adverse drug events (Ebrotidine (96) in 1998,
Grepaﬂoxacin (98) in 1999 or Cerivastatine (98) in
2001). CONCLUSIONS: The indicators used in this
study have permitted analyse the quality of the selection
of treatments ﬁnanced by public money. From the results
obtained, it would strongly recommend an urgent revi-
sion of type C (67.6%) new drugs ﬁnanced by NHS.
PHP17
SURVEY ON DRUG VALUE ASSESSMENT
AMONG PRESCRIBERS AND PAYERS IN ITALIAN
HOSPITALS
Negrini C, D’Ausilio A, Lopatriello S, Berto P
pbe consulting,Verona, Italy
OBJECTIVES: To identify and analyse elements on which
hospital decision makers base their therapy value assess-
ment, both in general terms and in relation to acute Heart
Failure (aHF)treatment. METHODS: Thirty face to face
interviews (15 hospital pharmacists and 15 cardiologists)
